Publications and Presentations
2000, 2001, 2002, 2003, 2005
(Fellows’ names bold)

Fellows

Publications:

Lallas TA, McClain S, Shahin MS, Buller RE.  The glutathione S-transferase mu-1 genotype in ovarian cancer.  Cancer Epi. Biomarker Preven.  9:587-590, 2000.

Raley J, Geisler JP, Buekers TE, Sorosky JI.  Docetaxel extravasation causing significant delayed tissue injury.  Gynecol Oncol.  78:259-260 2000.

Geisler JP, Sorosky JI.  Benign breast problems.  Prob Sur.  17:1-4, 2000.

Shahin MS, Sood AS, Hughes JH, Buller RE.  The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer.  Cancer.  89(9):2006-2017, 2000.

Shahin MS, BuekersTB, Sorosky JI, Anderson B, Buller RE.  Radical parametrectomy and pelvic lymphadnectomy in management of incidental cervical cancer.  J Pelvic Surg 6:210-213, 2000. 

Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK.  P53 mutations and microsatellite instability in ovarian cancer:  Yin and Yang.  Am J Obstet Gynecol 184:891-903, 2000.

Pertzborn S, Buekers TE, Sood AK. Hematogenous skin metastases from cervical cancer at primary presentation.  Gynecologic Oncology  76(3):416-417, 2000.

Lallas TA, McClain S, Shahin MS, Buller RE.  The glutathione S-transferase mu genotype inovarian cancer.  Cancer Epi. Biomarker Preven.  9:587-590, 2000.

Buekers TE, Lallas, TA, Buller RE.  Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.  Gynecologic Oncology 76:418-422, 2000.

Harms SA, Sood AK, Shahin M, Mayr N, Sorosky JI.  Bowel surgery after intraperitoneal 32P:  Is it safe to perform low colorectal anastomosis?  Journal of Gynecologic Techniques. 6(2):65-67, 2000.

Buekers TE, Sorosky JI, Anderson B, Buller RE.  Transabdominal biopsy in a poor prognostic factor in Stage IV ovarian carcinoma.  16(3):113-118, 2000.

Buller RE, Shahin MS, Holmes R, Hatterman M, Kirby PA, Sood AK.  P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang.  American Journal of Obstetrics and Gynecology. 184:891-903, 2001.

Buller RE, Lallas T, Shahin M, Sood AK, Hatterman M, Anderson B, Sorosky J, Kirby P.  The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.  Clinical Cancer Research.  7:831-838-, 2001.

Cooper B, Buekers TE, Buller RE, Sorosky JI.  Asymptomatic lung carcinoma presenting with a large vulvar lesion.  J. Lower Gen Disease.  5:48-50, 2001.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman M, Anderson B, Sorosky JI, Kirby PA.  Thep53 mutational spectrum associated with BRCA1 mutant ovarian cancer.  Clinical Cancer Research 7:831-838, 2001.

Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller.  Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.  gynecologic Oncology.  83(3):501-503, 2001.

Mahavni, V, Benda TA, Sanders L, Buller RE.  The androgen receptor and DXS 15-134 markers reveal a high rate of discordance for germline X chromosome inactivation.  38:474,478, 2001.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Lallas TA, Kirby P, Buller RE.    Ovarian cancer BRCA1 mutation detection: Protein Truncation Test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).  Human Mutation, 2001. 

Bender DP, Sood AK.  Chemoradiation for the treatment of cervical cancer:  A new paradigm.  Postgraduate Obstetrics and Gynecology.  21(19):1-5, 2001.

Sood AK, Shahin MS, Sorosky JI.  Paclitaxel and platinum chemotherapy during pregnancy for ovarian carcinoma.  Gynecologic Oncology.  83(3):599-600, 2001.

Mahavni V, Sood AK.  Hormone replacement and cancer risk.  Current Opinion in Oncology  13:384-389, 2001.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE.  Frequency of BRCA1 dysfunction in ovarian cancer.  J. Natl. Cancer Inst., 94:61-67, 2002.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE.  Ovarian cancer p53 mutation is associated with tumor microvessel density.  Gynecologic Oncology.  86:85-90, 2002.

Buller RE, Shahin MS, Horowitz JA, Mahavni V, Petrauska S, Runnebaum I, Krienberg R, Karlan B, Slamon D, Pegram M.  Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.  Cancer Gene Therapy, 9:567-575, 2002.

Lowe MP, Bender D, Sood AK, Davis W, Syrop C, Sorosky JI.  Delivery of twin gestations following conservative treatment of endometrial cancer and assisted reproduction.  Fertility and Sterility.  77(1):188-189, 2002.

Geisler JP, Sood AK, Holmes RJ, Hatterman-Zogg MA, Rathe JA, Buller RE.  hMLH1 promoter methylation contributes to microsatellite instability in ovarian cancer.  Clinical Cancer Research.  (Submitted)

Buller RE, Geisler JP, Shahin MS, Zogg Melanie, De Young BR, Davis CS.  Failure of BRCA1 dysfunction to alter ovarian cancer survival.  Clinical Cancer Research.  8:1196-1202, 2002.

Sood AK, Nygaard I, Shahin MS, Sorosky JI, Rao SSC.  Anorectal dysfunction after surgical treatment for cervical cancer.  The American Journal of Gastroeneterology.  195(4):513-519, 2002.

Rose SL, Buller RE.  The role of p53 mutation in BRCA1-associated ovarian cancer.  Minverva Ginecologica.  54:201-209, 2002.

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Blake LM, Buller RE.  P21 expression is an independent prognostic factor in p53 null ovarian carcinoma.  Clinical Cancer Research.  9:1028-1032, 2003.

Rose SL, Sorosky JI.  Cervical carcinoma complicating pregnancy.  Postgraduate Obstetrics and Gynecology.  23(11):1-7, 2003.

Rose SL, Robertson AD, Goodheart MJ, De Young BR, Smith BJ, Buller RE.  The impact of p53 structural alteration on ovarian cancer survival.  Clinical Cancer Research 9:4139-4144, 2003.

Stone PJB, Goodheart MJ, Rose SL, Smith BJ, DeYoung BR, Buller RE.  The influence of microvessel density on ovarian carcinogenesis.  Gynecologic Oncology.  90:556-571, 2003.

Chun ML, Buekers TE, Sood AK, Sorosky, JI. Postoperative wound infection with Pasteurella multocida from a pet cat.  American J Obstet Gynecol.  188:1115-1116, 2003.

Bender DP, Sorosky JI, Buller RE, Sood AK.  Serum CA125 is an independent prognostic factor in cervical adenocarcinoma.  American Journal of Obstetrics and Gynecology.  189(1):113-7, 2003.

Rose SL, Bunten CA, Geisler JP, Sood AK, Manahan KJ.  Mesh erosion in to the bowel and vagina following abdominal sacral colpopexy.  Am J Obstet Gynecol (submitted 2003).

Rose S, Goodheart M, DeYoung B, Smith B, Buller RE.  p21 expression predicts outcome in p53 null ovarian carcinoma.  Clinical Cancer Research 9:1028-1032, 2003.

Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clinical Cancer Research 9:4139-4144, 2003.

Geisler JP, Rose SL, Goodheart MJ, Bender DP, Sood AK, Sorosky JI, Manahan KJ. Operative and Short-Term Complications of Placement and Removal of Tunneled Central Venous Catheters on a Gynecologic Oncology Service. Gynecol Oncol (submitted 2003)

Geisler JP, Sood AK, Holmes RJ, Hatterman-Zogg MA, Rathe JA, Buller RE.  Mismatch repair gene expression defects contribute to microsatellite instability in ovarian cancer. Cancer.  98:2199-2206, 2003.

Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer, Vol 98, 2199-2206, November 2003

Geisler JP, Manahan KJ, Geisler HE, Tammela JE, Rose SL, Hiett AK, Miller GA, Wiemann C, Zhou Z. Heat Shock Protein 27 in the Placentas of Women with and without Severe Preeclampsia. Clinical and Experimental Obstetrics and Gynecology.  31(1):12-14, 2004.

Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Miller J, Crabtree W. Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. Int J Gynecol Oncol.  14(1):133-137, 2004.

Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ.  Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer.  Gynecologic Oncology.  96:470-474, 2005.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, DeYoung BR, Buller RE. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clinical Cancer Research.  11:3733-3742, 2005.

Bradley S, Rose S, Lutgendorf S, Costanzo E, Sorosky J, De Geest K, Anderson B.  Quality of life and mental health in cervical and endometrial cancer survivors.  (In Press).

Presentations - Fellows:

Shahin MS.  p53 tumor suppressor gene dysfunction is an important predictor of outcome in ovarian cancer. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2000.

Shahin MS. A case-matched molecular comparison of primary ovarian cancer versus primary peritoneal and fallopian tube carcinomas. The 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000.

Buekers TE, Lallas TA, Buller RE.  Germline mutations associate with X-chromosome LOH at Xpw2.2-3.  Poster presentation at the Annual Society of Gynecologic Oncologists meeting, 1999.

Buekers, TE.  Gene therapy in clinical practice. University of Missouri fourth annual oncology conference.  April, 1999.

Buekers, TE.  Ovarian function after radical hysterectomy.  First annual Margulis lecture series.  William Beaumont Hospital Department of Obstetrics and Gynecology.  June, 1999.

Geisler JP, Sood AK, Zogg MA, Holmes RJ, Rathe JA, RE Buller.  Ovarian cancer hMLH1 promoter methylation contributes to microsatellite instability   The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, Idaho 2001.

Geisler JP, Sorosky JI, Duong HL, Buekers T, Geisler MJ, Sood AK, Anderson B, Buller RE.  Papillary serous carcinoma of the uterus.  Increased risk for subsequent or concurrent development of breast carcinoma.  The 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, 2001.

Geisler JP.  A screening strategy to detect BRCA1 dysfunctiion in ovarian cancer.  The Annual Meeting of the Society of Gynecologic Oncologists, Nashville, Tennessee, March, 2001.

Shahin MS.  The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer.  Presentation the 31st Annual Society of Gynecologic Oncologist Meeting.  February, 2000.

Shahin MS.  A case-matched molecular comparison of primary ovarian cancer versus primary peritoneal and fallopian tube carcinomas.  Presentation at American Association for Cancer Research.  April, 2000.

Shahin MS.  Survival impact of multi-dose intraperitoneal (IP) RAD/P53 (SCH58500 gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer.  Presented at Western Association of Gynecologic Oncologists.  May, 2000.

Shahin MS.  Phase II Study of ON-Q Pain Management System in Patients Undergoing Surgery for Gynecologic Malignancy.  The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, Idaho, 2001.

Mahavni V. Lallas T., Buller R.E.  BRCA1 risk assessment.  Does The model work?  Twenty-eighth Annual Meeting of The Western Association of Gynecologic Oncologists (WAGO), Victoria, BC, 1999. 

Mahavni V.  Hormonally responsive and smoking related cancers show site-specific differences in the rate of non-random X Chromosomes inactivation.  Thirtieth Annual meeting of the Western Association of Gynecologic Oncologist.  Sun Valley, Idaho, June, 2001.

Bender DP, Sood AK, Sorosky JI, Anderson BA, Buller RE.  The value of pretreatment serum CA-125 in Cervical adenocarcinoma.  Presentation at the Western Association of Gynecologic Oncology, Sun Valley, Idaho, 2001.

Goodheart MJ.  Ovarian Cancer P53 Gene Mutations Are Associated with Increased Microvessel Density.  The 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, 2001.

Buller RE, Shahin M, Karlan B, Horowitz JA, Buekers TE, Salko T, Kerin M, Runnebaum I, Krienberg R, Slamon D, Pegram M.  Multi-dose intraperitoneal (IP) rAd/p53 (SCH58500) gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival.  5th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association.  Maui, Hawaii, February 2001.

Geisler JP, Lallas TA, Hatterman MA, Dolan MA, McClain S, Buller RE.  Screening for ovarian cancer BRCA1 mutations:  PTT is superior to SSCP.  5th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association.  Maui, Hawaii, February 2001.

Rodriguez JA, Shahin MS, Goodheart M, Buller RE.  Analysis of p53 structure-function effect on survival in ovarian cancer. Thirtieth Annual Meeting of The Western Association of Gynecologic Oncologists.  Sun Valley, Idaho.  2001.

Buller RE, Shahin MS, Horowitz JA, Mahavni V, Petrauskas S, Runnebaum I, Krienberg R, Karlan B, Slamon D, Pegram M.  SCH 58500 p53 gene replacement and recurrent ovarian cancer: long-term followup.  Society of Gynecologic Oncologists 32nd Annual Meeting.  Nashville, Tennessee, March, 2001.

Hilton, JL, Geisler, J, Zogg, M, McClean S, Buller RE.  Multiple mechanisms modify BRCA1 & BRCA2 expression in ovarian cancer. Society of Gynecologic Oncologists 32nd Annual Meeting.  Nashville, Tennessee, March, 2001.

Buller RE, Hilton J, Hatterman-Zogg M, Buller M, Geisler JP, DeYoung B.  Aberrant splicing of BRCA2 contributes to clear cell ovarian carcinoma and may represent another mechanism of BRCA2 dysfunction.  93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA. February, 2002. 

Buller, RE, Hilton J, Hatterman M, Buller M, Geisler J, DeYoung B.  Analysis of transcriptional profiling data by detection of activity centers in cellular pathways in ovarian clinical tissues with known p53 and BRCA1 status.  93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA. February, 2002. 

Goodheart MJ, Rose S, DeYoung B, Ritchie, J, Buller RE.  The relationship of molecular markers of p53 function and angiogenesis to prognosis of Stage I epithelial ovarian cancer.   Society of Gynecologic Oncologists’ 33rd Annual Meeting.  Miami Beach, FL.  March 2002. 

Buller RE, Geisler JP, Shahin MS, Hatterman-Zogg M, DeYoung B, Davis CS.  Failure of BRCA1 dysfunction to alter ovarian cancer survival.  Society of Gynecologic Oncologists’ 33rd Annual Meeting.  Miami Beach, FL.  March 2002.

Bender DP, Sood AK, Sorosky JI, Anderson B, Buller RE.  The prognostic value of a pretreatment serum CA-125 in cervical adenocarcinoma.  Society of Gynecologic Oncologists’ 33rd Annual Meeting.  Miami Beach, FL.  March 2002.

Bender DP, Kim S, Mahavni V, Zogg M, Sanders L, Buller RE.  Novel sites and markers enhance the detection of X-inactivation in ovarian cancer.  Thirty-first Annual Meeting of the Western Association of Gynecologic Oncologists.  Newport Beach, CA.  June, 2002, p 21, 2002.

Bender DP, Cooper BC, Sorosky JI, Sood AK.  Placental growth factor (PlGF) is a novel prognostic marker in ovarian cancer.  Poster at the 34th Annual Meeting for Society of Gynecologic Oncologists, January 2003.

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Blake LM, Buller RE.  The relationship between p21 expression and p53 gene mutation impacts ovarian cancer survival.  Thirty-first Annual Meeting of the Western Association of Gynecologic Oncologists.  Newport Beach, CA.  June, 2002, p 26, 2002.

Rose SL.  Long-term quality of life in cervical cancer survivors.  18th Annual Meeting of the Mid-Atlantic Gynecologic Society, Durham, NC, October 2003.

Geisler JP, Anderson BA, Buller RE, Geisler HE, Manahan KJ, Sorosky JI, Sood AK.  Is there a survival difference between patients with uterine papillary serous carcinoma and grade 3 endometrioid adenocarcinoma of the endometrium?  Thirty-first Annual Meeting of the Western Association of Gynecologic Oncologists.  Newport Beach, CA.  June, 2002, p 49, 2002.

Geisler JP.  RB1 and p53 nuclear staining and survival in patients with Stage III and IV epithelial ovarian carcinoma.  Society of Memorial Gynecologic Oncologists, New York, NY, September, 2002. 

Geisler JP.  A case-control retrospective comparative analysis of primary carcinoma of the fallopian tube and epithelial ovarian carcinoma.  Society of Memorial Gynecologic Oncologists, New York, New York, September, 2002.

Geisler JP.  RB1 and p53 nuclear staining and survival in patients with Stage III and IV epithelial ovarian carcinoma.  Society of Memorial Gynecologic Oncologists, New York, NY, September, 2002. 

Geisler JP.  A case-control retrospective comparative analysis of primary carcinoma of the fallopian tube and epithelial ovarian carcinoma.  Society of Memorial Gynecologic Oncologists, New York, New York, September, 2002.

Geisler JP, Rose SL, Goodheart MJ, Sorosky JI, Anderson B, Buller RE, Manahan KJ. Operative and Short Term Complications of Tunneled Central Venous Catheters on a Gynecologic Oncology Service. Society of Gynecologic Oncologists- New Orleans, LA: January, 2003.

Buller RE, Burns B, Geisler JP, Hatterman-Zogg M, DeYoung B.  Ovarian mixed mullerian tumor (MMT) is a component of hereditary BRCA-related ovarian cancer and a possible clue to BRCA3.  Society of Gynecologic Oncologists- New Orleans, LA: January, 2003.

Geisler JP, Rose SL, Buller RE, Manahan KJ. Estrogen receptor and expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. American Association for Cancer Research-Toronto, ON, Canada: January, 2003.

Geisler JP, Dunn MS, Sorosky JI, Anderson B, Buller RE, Manahan KJ. A Case-Control Retrospective Comparative Analysis of Primary Carcinoma of the Fallopian Tube and Epithelial Ovarian Carcinoma. American College of Obstetricians and Gynecologists- New Orleans, LA: May, 2003.

Goodheart MJ, Rose SL, Fruehauf JP, Smith BJ, Anderson B, Buller RE.  Western Association of Gynecologic Oncologists, Steamboat Springs, Colorado.  The relationship of Thrombospondin-1 to risk factors in ovarian carcinoma.  2003.

Goodheart MJ, Rose SL, Hatterman-Zogg MA, Smith BJ, De Young BR, Sorosky JI, Buller RE.  BRCA2 alteration is important in clear cell carcinoma of the ovary.  Mid-Atlantic Gynecologic Oncologic Society, Durham, North Carolina.  2003.

Goodheart MJ, Rose SL, Hatterman-Zogg MA, Smith BJ, De Young BR, Sorosky JI, Buller RE.  BRCA2 alteration is important in clear cell carcinoma of the ovary.Floor presentation, Society of Gynecologic Oncologists, San Diego, California.  2004.

Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B.  Long-Term Quality of Life in Cervical Cancer Survivors.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B.  The Impact of Adjuvant Radiation Therapy on Long-Term Quality of Life in Patients with Stage I Endometrial Cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE.  Maspin expression is activated by loss of promoter methylation in ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Goodheart M, Rose SL, Smith BJ, De Geest K.  Microvessel density is a marker of biological difference between mucinous and nonmucinous epithelial ovarian carcinjoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Abstracts – Faculty with Fellows

Bradley SL, Rose SL, Costanzo E, Anderson B, Lutgendorf SK.  Depression and Mood in   Long-Term Survivors of Cervical and Endometrial Cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE.  Maspin expression is activated by loss of promoter methylation in ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Goodheart M, Rose SL, Smith BJ, De Geest K.  Microvessel density is a marker of biological difference between mucinous and nonmucinous epithelial ovarian carcinjoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Goodheart MJ, Rose SL, Smith BJ, DeGeest K.  Microvessel density is a marker of biological difference between mucinous and non-mucinous epithelial ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami Beach, Floria, March 2005.

Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE.  Maspin Expression is Activated by Loss of Promoter Methylation in Ovarian Carcinoma.  Society of Gynecologic Oncologists.  Miami Beach, Florida, March 2005.

Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B.  Long-Term Quality of Life in Cervical Cancer Survivors.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B.  The Impact of Adjuvant Radiation Therapy on Long-Term Quality of Life in Patients with Stage I Endometrial Cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Bradley SL, Rose SL, Costanzo E, Anderson B, Lutgendorf SK.  Depression and Mood in Long-Term Survivors of Cervical and Endometrial Cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.

Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE.  Maspin expression is activated by loss of promoter methylation in ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Goodheart M, Rose SL, Smith BJ, De Geest K.  Microvessel density is a marker of biological difference between mucinous and nonmucinous epithelial ovarian carcinjoma.  Society of Gynecologic Oncologists.  Miami, Florida.  March 2005.

Fellow Honors

• Geisler, JP,  2000.  Papillary Serous Carcinoma of the Uterus: Increased Risk of Subsequent or Concurrent Development of Breast Carcinoma. Leo D Lagasse Award for the Best Presentation by a fellow – Western Association of Gynecologic Oncologists Meeting, Monterey, California, 2000.
• Goodheart, MJ, 2003.  Received James Roberts Scholarship Fund.  Thirty-Second Annual Meeting of the Western Association of Gynecologic Oncologists, Steamboat Springs, Colorado.
• Rose, Stephen 2003.  Recipient of a scholarship to attend the Molecular Biology in Clinical Oncology AACR Workshop, Aspen, CO, 2003
• Rose, Stephen, 2004.  Best Fellow Presentation, Mid-Atlantic Gynecologic Oncology Society, Durham, North Carolina, 2004.
• Rose, Stephen, 2005   Best Postdoctoral Fellow Presentation, The University of Iowa Research Week, Iowa City, IA, 2005
• Rose, Stephen,  Recipient of 2005 Fellows Educational Grant to attend The SGO 2005 Annual Meeting on Women’s Cancer, Miami, FL.
• Goodheart, Michael, 2000-present  T32 Research Training Grant, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. 
• Goodheart, Michael, 2004.  Teaching Recognition-Third year medical school class.  University of Iowa, Iowa City, Iowa. 

  ---

Faculty Publications and Presentations
2000 - 2005

Publications - Faculty:

Shahin MS, Sorosky JI, Buekers T, Anderson B, Buller RE.  Radical parametrectomy and pelvic lymphadenectomy in incidental cervical carcinoma.  J Pelvic Surg.  6:210-213, 2000.

Sood AK, Sorosky, JI, Mayr N, Anderson B, Buller RE, Niebyl J.  Cervical cancer diagnosed shortly after pregnancy:  Prognostic variables and delivery route.  Obstetrics and Gynecology 95:832-838, 2000.

Connor JP, Andrews JI, Anderson B, Buller RE.  Computed tomography in endometrial cancer.  Obstet Gynecol 95:692-6, 2000. 

Buller RE.  BRCA1:  What do we know?  What do we think we know?  What do we really need to know?  Gynecologic Oncology.  76:291-3, 2000.

Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE.  Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva.  Cancer.  89(7):1520-1525, 2000.

Pertzborn S, Buekers TE, Sood AK.  Hematogenous skin metastases from cervical cancer at primary presentation.  Gynecologic Oncology  76(3):416-417, 2000.

Harms SA, Sood AK, Shahin M, Mayr N, Sorosky JI.  Bowel surgery after intraperitoneal 32P:  Is it safe to perform low colorectal anastomosis?  Journal of Gynecologic Techniques. 6(2):65-67, 2000.

Shahin MS, Hughes JM, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer. Cancer.  89(9):2006-2017, 2000.

Mayr NA, Yuh WTC, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JM.  Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer.  Journal of Magnetic Resonance Imaging. 12:1027-1033, 2000.

Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE.  Long term central venous access in gynecologic cancer patients.  Journal of the American College of Surgeons  191:403-409, 2000.

Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI.  Quality of life and mood in women heavily treated for gynecologic cancer.  Cancer  89:1402-11, 2000.

Raley J, Geisler JP, Buekers TE, Sorosky JI.  Docetaxel extravasation causing significant delayed tissue injury.  Gynecol Oncol.  78:259-260, 2000.

Buekers TE, Lallas TA, Buller RE.  Xp22-2.-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.  Gynecologic Oncology.  76:418-422, 2000.

Lallas T, McClain SK, Shahin MS, Buller RE.  Gluthathione s-transferase Mu polymorphism and their relationship with ovarian cancer.  Cancer Epidem Biomark & Prev.  9:587-590, 2000.

Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE.  Preservation of saphenous vein in inguinal lymphadenectomy decreases morbidity in vulvar cancer patients.  Cancer  89:1520-1525, 2000.

Lowe MP, Ault KA, Sood AK.  Recurrent carcinoma in situ of neovagina.  Gynecologic Oncology. 80:403-404, 2001.

Buekers TE, Sorosky JI, Anderson B, Buller RE.  Transabdominal biopsy in a poor prognostic factor in Stage IV ovarian carcinoma.  16(3):113-118, 2000.

Buller, RE.  BRCA1:  What do we know?  What do we think we know?  What do we really need to know?  Gynecologic Oncology. 76, 291-3,  2000.

Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJS, Vermorken JB, Wells M, Wilbanks GD.  Chromosomal abnormalities as prognostic factors in ovarian cancer.  Consensus statements on prognostic factors in epithelial ovarian carcinoma.  Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.  Eur J Gynaec Oncol  21(5):521, 2000.

Mayr NA, Sood AK.  Chemo-Radiation Therapy in Cervical Cancer:  Where do we go from here?  Invited commentary for “Combined chemo-radiation for locally advanced cancer of the cervix”.  Oncology  1336-1338, 2000.

Lutgendorf SK, Anderson B, Buller R, Sorosky JI, Lubaroff D.  Interleukin-6 and use of social support in gynecologic cancer patients.  International Journal of Behavioral Medicine. 7(2):127-142, 2000.

Bender DP, Sood AK.  Chemoradiation for the treatment of cervical cancer:  A new paradigm.  Postgraduate Obstetrics and Gynecology.  21(19):1-5, 2001.

Sood AK, Shahin MS, Sorosky JI.  Paclitaxel and platinum chemotherapy during pregnancy for ovarian carcinoma.  Gynecologic Oncology.  83(3):599-600, 2001.

Mahavni V, Sood AK.  Hormone replacement and cancer risk.  Current Opinion in Oncology  13:384-389, 2001.

Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE.  Papillary serous carcinoma of the uterus:  Increased risk of subsequent or concurrent development of breast carcinoma.  Gynecologic Oncology.  83(3):501-503, 2001.

Buekers, TE, Anderson B, Sorosky, JI, Buller, RE.  Ovarian function after surgical treatment for cervical cancer.  Gynecol Oncol  80:85-22, 2001.

Mahavni V, Benda TA, Sanders L, Buller RE.  The androgen receptor and DXS 15-134 markers reveal a high rate of discordance for germline X chromosome inactivation.  J Med Genetics  38:474-478, 2001.

Cooper B, Buekers TE, Buller RE, Sorosky JI.  Asymptomatic lung carcinoma presenting with a large vulvar lesion.  J.  Lower Gen Disease.  5:48-50, 2001.

Zaino R, Witney C, Brady MF, DeGeest K, Burger RA, Buller RE.  Simultaneously detected endometrial and ovarian carcinomas – a prospective clinicopathologic study of 74 cases:  A Gynecologic Oncology Group Study.  Gynecol Oncol 83:355-362, 2001.

Buller RE, Shahin MS, Holmes R, Hatterman M, Kirby PA, Sood AK.  P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang.  American Journal of Obstetrics and Gynecology. 184(5):891-903, 2001.

Buller RE, Lallas T, Shahin M, Sood AK, Hatterman M, Anderson B, Sorosky J, Kirby P.  The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.  Clinical Cancer Research.  7:831-838, 2001.

Sood AK, Seftor EA, Fletcher M, Gardner LMG, Heidger PM, Seftor REB, Buller RE, Hendrix MJC.  Molecular determinants of ovarian cancer plasticity.  American Journal of Pathology.  158:1179-1288, 2001.

Sood AK, Holmes RW, Hendrix MJC, Buller RE.  Application of the NCI international criteria for determination of microsatellite instability in ovarian cancer.  Journal of the National Cancer Institute.  61(11):4371-4374, 2001.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Lallas TA, Kirby P, Buller RE.  Ovarian cancer BRCA1 mutation detection:  protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).  Human Mutation.  18(4):337-344, 2001.

Braithwaite SS, Bitterman P, De Geest K¸ Lebbin DR.  Postmenopausal virilization, simple ovarian cyst, hilus cell hyperplasia, is there an association?  Endocrine Practice 7(1), 40-43,  2001.

Smith SA, Richards WE, Caito K, Hanjani P, Markman M, De Geest K, and Gallion, HH.  BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases:  A Gynecologic Oncology Group Study, Gynecol Oncol 83: 586-92, 2001

Curtin JP, Blessing JA, Soper JT, De Geest K.  Paclitaxel in the treatment of carcinosarcoma of the uterus.  Gynecol Oncol  83 : 268-70, 2001

Anderson J, Behbakht K, De Geest K, Bitterman P.   Adenosarcoma in a patient with vaginal endometriosis.  Obstet Gynecol, 98, 964-966, 2001.

Lutgendorf SK, Anderson B, Ullrich P, Johnsen E, Buller RE, Sood AK, Sorosky JI, Ritchie J.  Quality of life and mood in women with gynecologic cancer.  Cancer.  94(1):131-140, 2002.

Lowe MP, Bender D, Sood A, Davis W, Syrop CH, Sorosky J.  Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction.  Fertility and Sterility.  77(1):188-189, 2002.

Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J.  Randomized trial of cisplatin and Ifosfamide versus cisplatin, Ifosfamide, and bleomycin in advanced squamous cell carcinoma of the uterine cervix:  A Gynecologic Oncology Group study.  Journal of Clinical Oncology.  20(7):1832-1837, 2002.

Geisler JP, Sood AK, Holmes RJ, Hatterman-Zogg MA, Rathe JA, Buller RE.  hMLH1 promoter methylation contributes to microsatellite instability in ovarian cancer.  Clinical Cancer Research.  (Submitted)

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE.  Ovarian Cancer p53 Mutation is Associated with Tumor Microvessel Density.  Gynecologic Oncology.  86(1):85-90, 2002.

Sood AK, Nygaard I, Shahin MS, Sorosky JI, Rao SSC.  Anorectal dysfunction after surgical treatment for cervical cancer.  The American Journal of Gastroenterology.  195(4):513-519, 2002.

Fracasso PM, Blessing JA, Molpus K, Adler LM, Sorosky JI, Rose PG.  Phase II study of oxaliplatin in advanced or recurrent endometrial carcinoma:  A Gynecologic Oncology Group Study.  Submitted 2002.

Jondle DM, Shahin MS, Sorosky J, Benda JA.  Ovarian mixed germ cell tumor with predominance of polyembryoma:  a case report with literature review.  Int J Gynecol Path.  21:78-81, 2002.

Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK.  Vascular Endothelial Growth Factor and Social Relationships in Ovarian Cancer Patients.  Cancer 95(4):809-815, 2002.

Sood AK, Fletcher MS, Hendrix MJC.  The embryonic-like properties of aggressive human tumor cells.  Journal of the Society for Gynecologic Investigation.  9(1):2-9, 2002.

Buller RE, Geisler JP, Shahin MS, Zogg Melanie, De Young BR, Davis CS.  Failure of BRCA1 dysfunction to alter ovarian cancer survival.  Clinical Cancer Research.  8:1196-1202, 2002.

Buller RE, Slamon D, Runnebaum I, Horowitz, JA, Buekers T, Salko, T, Petrauskas S, Shahin M, Kreienberg R, Karlan B, Pegram M.  A Phase I/II trial of rAd/p53 (SCH 58500) Gene Replacement in recurrent ovarian cancer. Cancer Gene Ther 9:553-566, 2002.

Buller RE, Shahin MS, Horowitz JA, Runnebaum I, Mahavni V, Petrauskas S, Krienberg R, Karlan B, Slamon D, Pegram M.  Long term follow-up of patients with recurrent ovarian cancer after rAd p53 gene replacement with SCH 58500.  Cancer Gene Ther 9:567-575, 2002.

Muggia FM, Blessing JA, Sorosky JI, Reid GC.  Phase II trial of pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer.  J Clin, Oncol 20:2360-2364, 2002.

Hilton JL, Hattermann-Zogg MA, McClain S, Buller RE.  Multiple mechanisms modify BRCA1 & BRCA2 expression in ovarian cancer.  J Natl Cancer Inst 94:18):1395-1406, 2002.

Dong LJ, Chen Y, Lewis M, Hsieh JC, Reing J, Chaillet R, Howell K, Melhem M, Inoue S, Kuszak JR,

De Geest K and Chung AE.  Deficiencies in neuromuscular control and selected disruption of basement membranes in mice lacking entactin-1.  Lab Invest, 82,1617-1620, 2002.

Plaxe S, Blessing J, Olt G, Husseinzadek N, Lentz S, De Geest K, Valea F.  Phase II Trial of Pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix:  A Gynecologic Oncology Group Study, Cancer Chemother. and Pharmacol.  50(2):151-154, 2002.

Cooper BC, Sood AK, Davis C, Ritchie J, Sorosky JI, Anderson B, Buller RE.  Preoperative CA125 levels.  An independent prognostic factor in epithelial ovarian cancer.  Obstet Gynecol 100(1):59-64, 2002.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE.  Frequency of BRCA1 dysfunction in ovarian cancer.  J Natl Cancer Inst 94: 61-67, 2002.

Cooper BC, Ritchie JM, Broghammer CLW, Coffin J, Sorosky JI, Anderson B, Buller RE, Sood AK.  Preoperative serum vascular endothelial growth factor (VEGF) levels:  significance in ovarian cancer. Clinical Cancer Research.  8:3193-3197, 2002.

Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, Sorosky JI, Meeks SL, Buatti JM.  Method and timing of tumor volume measurement for outcome prediction in cervical cancer using MR imaging.  Int J Radiat Oncol Biol Phys.  52(1):14-22, 2002.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE.  Ovarian Cancer p53 mutations predict tumor microvessel density. Gynecologic Oncology.  86:85-90, 2002.

Buller R, Shahin M, Geisler J, Zogg M, Rathe JA, De Young B, Davis C.  Failure of BRCA1 dysfunction to alter ovarian cancer survival.  Clin Cancer Res 8:1196-1202, 2002.

Rose SL, Buller RE.  The role of p53 mutation in BRCA1-associated ovarian cancer.  Estratto da Minerva Ginecologica.  54:201-209, 2002.

Chun ML, Buekers TE, Sood AK, Sorosky, JI. Postoperative wound infection with Pasteurella multocida from a pet cat.  American J Obstet Gynecol.  188:1115-1116, 2003.

Lowe MP, Cooper BC, Sood, AK, Davis WA, Syron CH, Sorosky JI.  Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.  Gynecologic Oncology.  91(3):569-572, 2003.

Rose SL, Sorosky JI.  Cervical carcinoma complicating pregnancy.  Postgraduate Obstetrics and Gynecology.  23(11):1-7, 2003.

Bender DP, Sorosky JI, Buller RE, Sood AK.  Serum CA125 is an independent prognostic factor in cervical adenocarcinoma.  American Journal of Obstetrics and Gynecology.  189(1):113-7, 2003.

Adli M, Mayr NA, Kaiser HS, Skwarchuk MW, Meeks SL, Mardirossian G, Paulino AC, Montebello JF, Gaston RC, Sorosky JI, Buatti JM.  Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer?  Int. J Radiation Oncology Biol Phys.  57(1):230-238, 2003.

Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, De Geest K, Moore DH.  A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma:  A Gynecologic Oncology Group Study.  Gynecol Oncol  88(2):130-135, 2003.

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, De Geest K, Hartenbach EM, Baergen, R. Phase III trial of carboplatin and paclitaxel compared with optimally resected stage III ovarian cancer. J Clin Oncol.  21(17):3194-3200, 2003.

Behbakht K, San Juan AA, De Geest K, Massad, LS. A comparison of cervical cancer survival between urban Caucasian and Asian-American women. Gynecol Oncol, submitted.

Geisler JP, Rose SL, Goodheart MJ, Bender DP, Sood AK, Sorosky JI, Manahan KJ.  Operative and Short-Term Complications of Placement and Removal of Tunneled Central Venous Catheters on a Gynecologic Oncology Service. Gynecol Oncol (submitted 2003)

Geisler JP, Rather JA, Manahan KJ. Methylation: A Second Hit in the Two Hit Hypothesis. Eur J Gynaecol Oncol. 24(5):361, 2003.

Geisler JP, Manahan KJ, Geisler HE, Tammela JE, Rose SL, Hiett AK, Miller GA, Wiemann C, Zhou Z. Heat Shock Protein 27 in the Placentas of Women with and without Severe Preeclampsia.  Clinical & Experimental Obstetrics & Gynecology.  31(1):12-4, 2004.

Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML.  Evaluation of vinorelbine in persistent or recurrent nonsquamous cell carcinoma of the cervix: A gynecologic Oncology Group Study.  Gynecologic Oncology  92(2):639-643, 2004.

Geisler HE, Young SR, Alley CT, Manahan KJ, Geisler JP. Pre-operative Evaluation in Patients with Gynecologic Malignancies. CME J Gynecol Oncol.31(1):12-14, 2004.

Geisler JP, Geisler HE, Manahan KJ. Pseudomyxoma peritonei. CME J Gynecol Oncol 2003 (accepted for publication)

Rose SL, Bunten CA, Geisler JP, Sood AK, Manahan KJ. Mesh Erosion into the Bowel and Vagina Following Abdominal Sacral Colpopexy. Am J Obstet Gynecol  (submitted 2003)

Galili U, Chen Z, De Geest K.  Expression of a-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.  Gynecol Oncol.  90:100-108, 2003.

Dong L, Blazek ER, Li JL, Pessin J, Subbaiah S, Sappelsa L, De Geest K.  DNA double-strand break rejoining and HsRad51 nuclear focus formation in ultra-radiosensitive M059J cells.  Radiation Research, submitted.

Hsy Y, Sood AK, Sorosky JI.  Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer:  case-control analysis of toxicity.  American Journal of Clinical Oncology.  27(1):14-18, 2004.

Eichholz AC, Van Voorhis BJ, Sorosky JI, Smith BJ, Sook AK.  Operative note dictation:  should it be taught routinely in residency programs?  Obstetrics & Gynecology.  103(2):342-346, 2004

Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB.  Gynecologic Oncology Group.  Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma:  A Gynecology Oncology Study.  Gynecologic Oncology.  92(1):4-9, 2004.

Geisler JP, Schraith DF, Manahan KJ, Sorosky JI.  Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.  Gynecologic Oncology.  92(2):705-707, 2004.

Thigpen JT, Blessing JA, De Geest K, Look KY, Homesley HD.  Cisplatin as initial chemotherapy in ovarian carcinosarcomas:  A Gynecologic Oncology Group Study.  Gynecol Oncol.  93:336-339, 2004.

Behbakht K, Lynch A, Teal S, De Geest K, Massad LS. Social and cultural barriers to Papanicolaou smear screening in an urban population. Obstet Gynecol. 104:1355-1361, 2004.

Greer B, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, De Geest K, Hartenbach EM, Baergen R, Copeland LJ.  Implications of second-look laparotomy in the context of protocol 158.  A non-randomized comparison using an  explanatory analysis:  a Gynecologic Oncology Group Study.  Y. Clin Oncol, Submitted.

Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Lubaroff DM.  Biobehavioral correlates of natural killer cell activity in three compartments in ovarian cancer patients.  (Submitted).

Costanzo ES, Lutgendorf S, Sook AK, Anderson B, Lubaroff DM.  Psychosocial factors and Interleukin-6 among women with advanced ovarian cancer.  Cancer.  104(2):305-313, 2005. 

Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Lubaroff DM.  Social support, distress, and natural killer cell activity in ovarian cancer patients (revise and resubmit) Journal of Clinical Oncology.

Bradley S, Rose S, Lutgendorf S, Costanzo E, Sorosky J, De Geest K, Anderson B.  Quality of life and mental health in cervical and endometrial cancer survivors.  Gynecologic Oncology. 100(3):479-486, 2006.

Publications – Faculty (continued):

Costanzo E, Lutgendorf S, Rothrock N, Anderson B.  Coping and quality of life among women extensively treated for gynecologic cancer.  Psycho-Oncology.  15:132-142, 2006.

Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K, Domann FE.  Epigenetic regulation of Maspin expression in human ovarian carcinoma cells.  (submitted).

Presentations - Faculty

Hilton JL, Buller R.E.  Multiple mechanisms modify BRCA1/BRCA2 expression in ovarian cancer.  Western Association of Gynecologic Oncologists 29th Annual Meeting, Monterey, CA, 2000.

Buller R.E.  P53 null mutations:  further explorations.  91st Annual Meeting of the American Association for Cancer Research, Inc. San Francisco, CA April, 2000.       

Buller R.E.  Multi-dose intraperitoneal (ip) rad/p53 (sch58500) gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival.  Ninth International Conference on Gene Therapy of Cancer.  Coronado, California.  December, 2000.

Buller R.E.  Multi-dose intraperitoneal (ip) rad/p53 (sch58500) gene replacement combined with platinum-based chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival. 

Molecular Biology and New Therapeutic Strategies:  Cancer Research in the 21st Century

5th Joint Conference with the AACR and Japanese Cancer Association.  Maui, Hawaii.  February, 2001.

Buller R.E.  SCH 58500 p53 gene replacement and recurrent ovarian cancer: Long-term follow-up.  Society of Gynecologic Oncologists – 32nd Annual Meeting.  Nashville, Tennessee.  March, 2001.

Buller R.E.  Comparative survival among germline and somatic BRCA1 associated ovarian cancer controlled for p53 mutations status.  92nd Annual Meeting of the American Association of Cancer Research.  New Orleans, Louisiana.  2001.

Buller R.E.  Comparative survival among germline and somatic BRCA1 associated ovarian cancers. Thirtieth Annual Meeting of The Western Association of Gynecologic Oncologists.  Sun Valley, Idaho.  2001

Buller R.E.  Multi-dose intraperitoneal (IP) RAD/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival.  International Society of Gene Therapy & Molecular Biology, Corfu, Greece, August, 2001.

Buller RE.  Observations on bringing gene therapy from limited access Phase I/II trials to the level of a multinational Phase III trial.  Tenth International Conference on Gene Therapy of Cancer.  Coronado, CA.  December 2001. 

Buller RE. Aberrant splicing of BRCA2 contributes to clear cell ovarian carcinoma and may represent another mechanism of BRCA2 dysfunction.  93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA. February, 2002. 

Buller, RE.  Analysis of transcriptional profiling data by detection of activity centers in cellular pathways in ovarian clinical tissues with known p53 and BRCA1 status.  93rd Annual Meeting of the American Association of Cancer Research, San Francisco, CA. February, 2002. 

Buller RE.  Failure of BRCA1 dysfunction to alter ovarian cancer survival.  Society of Gynecologic Oncologists’ 33rd Annual Meeting.  Miami Beach, FL.  March 2002.

Buller RE.  Ovarian cancer risk assessment.  PJD Symposium.  Univeristy of California, Irvine.  Newport Beach, CA.  November, 2002. 

Buller RE.  The hereditary ovarian cancer genes BRCA1/BRCA2 are prime targets for gene therapy strategies to treat all ovarian cancers.  Eleventh International Conference on Gene Therapy of Cancer.  San Diego, CA.  December, 2002.

Anderson B.  Colorado Gynecological & Obstetrical Society, Denver, CO.  Quality of Life in Ovarian Cancer Patients.  January, 2000.

Anderson B.  Grand Round, Department of Obstetrics & Gynecology, Rose Medical Center, CO.  Management of the Ovary at Hysterectomy.  January, 2000.

Anderson B.  Grand Rounds, Department of Obstetrics & Gynecology, University of Colorado Health Sciences Center.  Familial Ovarian Cancer.  January, 2000.

Anderson B.  Resident Seminar, Department of Obstetrics & Gynecology, University of Colorado Health Sciences Center.  Quality of Life in Gynecologic Cancer Patients.  January, 2000

Anderson B.  University of Iowa COM Visiting Professor.  Siouxland Medical 

Education Foundation, Sioux City, IA. – Ovarian Cancer for the Generalist.  February 8, 2001.

Anderson B.  University of Arizona. Visiting Professor.  University of Arizona, Tucson, Arizona.  Quality of Life in Ovarian Cancer.  January 30, 2002.

Anderson B.  January 30, 2002.  University of Arizona.  Visiting Professor.  University of Arizona, Tucson, Arizona.  Management of Ovarian Cancer. 

Anderson B.  May 8, 2002.  University of Iowa COM Visiting Professor.  Mason City, IA. 

Management of Asymptomatic Pelvic Mass.  May 8, 2002.

Sorosky JI, Sood AK, Shahin M, Anderson B.  Medicinal leech therapy.  The Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Pittsburgh, PA, 2001.

Sorosky JI,  “Cervical Cancer Complicating Pregnancy”, Grand Rounds, Department of Obstetrics & Gynecology, University of Louisville, January 23, 2001.

Presentations – Faculty (continued):

Sorosky JI, “Abnormal Pap Smears Complicating Pregnancy”, ACOG Annual Meeting, Chicago Illinois, May 2001.

Sorosky JI, “Tamoxifen: The Good, The Bad, and the Ugly”, ACOG Annual Clinical Meeting, Chicago, Illinois, May 2001.

Sorosky JI, “Breast Disease Complicating Pregnancy”, ACOG Annual Clinical Meeting, Chicago, Illinois, May 2001.

Sorosky JI, “Pap Smears that complicate pregnancy”, Maurice Grier Symposium, Creighton University School of Medicine, Omaha, Nebraska, June 16, 2001.

Sorosky JI, “Academic Career Development”. Society of Gynecologic Oncologists Annual Meeting, Miami, Florida, March 17, 2002

Sorosky JI, “Screening Women for Cancer”, Broadlawns Medical Center, Des Moines, Iowa March 27, 2002.

Sorosky JI, “ Control of Hemorrhage in the Operating Room”, University of Iowa Ob-Gyn Postgraduate Course, Iowa City, Iowa  September 7, 2002.

Sorosky JI, “Duty Hours, Competencies and the Obstetrician Gynecologist”, University of Virginia, Grand Rounds, Department of Obstetrics and Gynecology, Charlottesville, Virginia, September 11, 2002.

Sorosky JI, “Duty Hours, Competencies and the Obstetrician Gynecologist”, University of Connecticut, Grand Rounds, New Britain Hospital, Department of Obstetrics and Gynecology, New Britain, Connecticut, March 19, 2003.

Sorosky JI, “Management of the Abnormal Pap Smear During Pregnancy”, University of Connecticut, Grand Rounds, Department of Obstetrics and Gynecology, Hartford, Connecticut, March 20, 2003.

Sorosky JI, “Duty Hours, Competencies and the Obstetrician Gynecologist”, University of Connecticut, Hartford Hospital, Grand Rounds, Department of Obstetrics and Gynecology, Hartford, Connecticut, March 20, 2003.

Sorosky JI, “Genetic Screening for Gynecologic Malignancies”, American College of Obstetricians and Gynecologists, Annual Clinical Meeting, New Orleans, Louisiana, April 28, 2003.

Sorosky JI, “Prophylactic Surgery for Gynecologic Malignancies”, American College of Obstetricians and Gynecologists, Annual Clinical Meeting, New Orleans, Louisiana, April 29, 2003.

Sorosky JI, “Palliative Care for Gynecologic Malignancies”, American College of Obstetricians and Gynecologists, Annual Clinical Meeting, New Orleans, Louisiana, April 30, 2003.

Sorosky JI, “Management of the Abnormal Pap Smear During Pregnancy”, American College of Obstetricians and Royal College of Obstetricians an dGynaecologists Combined Meeting, London, England, September 20, 2003.

Sorosky JI, “Cervical Cancer Complicating Pregnancy”, University of Iowa Department of Obstetrics and Gynecology Postgraduate Course, Iowa City, Iowa, September 26, 2003.

Sorosky JI,  “Management of Incidental Gynecologic Pathology during Laparotomy”, University of Iowa Department of Surgery Postgraduate Course, Iowa City, Iowa, November 14, 2003.

Sorosky JI,  “Cervical Cancer Complicating Pregnancy”, Grand Rounds, The University of Iowa Department of Obstetrics and Gynecology, January 20, 2004.

Behbakht K, Massad LS, Abu-Rustum N, De Geest K.  Social and cultural barriers to Papanicolau smear in an urban population. Annual meeting of the American Society for Colposcopy and Cervical Pathology, March 2002.

De Geest K, Galili U. A novel ovarian carcinoma vaccine with alpha-galactosyl modified autologous tumor cell membranes. Ninth Biennial Meeting of the International Gynecological Cancer Society, October 20 – 24, Seoul, Korea. Int  J Gynecol Cancer 2002,12, 562.

Dong LJ, De Geest K. Hyperproliferation and lineage shift of lymphoid cells in mice lacking the basement membrane protein entactin-1/ nidogen-1. AACR Annual Meeting, Toronto, April 2003.

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Blake LM, Buller RE.  P21 Expression is an Independent Prognostic Factor in p53 Null Ovarian Carcinoma.  Clinical Cancer Research  9:1028-1032, 2003.

Rose SL, Robertson AD, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE.  The Impact of p53 Structural Alteration on Ovarian Cancer Survival.  Clinical Cancer Research  9: 4139-4144, 2003.

Rose SL, Bunten CA, Geisler JP, Sood AK, Manahan KJ.  Mesh erosion in to the bowel and vagina following abdominal sacral colpopexy.  Am J Obstet Gynecol (submitted 2003).

Stone PJB, Goodheart MJ, Rose SL, Smith BJ, DeYoung BR, Buller RE.  The Influence of Microvessel Density on Ovarian Carcinogenesis.  Gynecologic Oncology  90: 566-571, 2003.

Rose S, Goodheart M, DeYoung B, Smith B, Buller RE.  p21 expression predicts outcome in p53 null ovarian carcinoma.  Clinical Cancer Research 9:1028-1032, 2003.

Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clinical Cancer Research 9:4139-4144, 2003.

Rose SL, Bradley SL, Lutgendorf SK, Sorothy JI, Anderson B.  Long-term quality of life in cervical cancer survivors.  Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA  2004.

Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B.  The impact of adjuvant radiation therapy on long-term quality of life in patients with Stage I endometrial cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA  2004.

Bradley SL, Rose SL, Costanzo E, Anderson B, Lutgendorf SK.  Depression and mood in long-term survivors of cervical and endometrial cancer.  35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA  2004.

Goodheart MJ, Rose SL, Smith BJ, DeGeest K.  Microvessel density is a marker of biological difference between mucinous and non-mucinous epithelial ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami Beach, Floria, March 2005.

Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE.  Maspin Expression is Activated by Loss of Promoter Methylation in Ovarian Carcinoma.  Society of Gynecologic Oncologists.  Miami Beach, Florida, March 2005.

Goodheart M, Rose SL, Smith BJ, De Geest K.  Microvessel density is a marker of biological difference between mucinous and nonmucinous epithelial ovarian carcinoma.  Society of Gynecologic Oncologists.  Miami, Florida, March 2005.